摘要:
The present invention relates to a novel process for preparing (E)-1-amino-2-(fluoromethylene)-4-(p-fluorophenyl)butane, also known in the art as (E)-(p-fluorophenethyl)-3-fluoroallylamine, novel intermediates thereof, a novel process for the preparing (E)-2-(fluoromethylene)-4-(p-fluorophenyl)butan-1-ol, a novel process for preparing alkali metal salts of diformylamide, and a novel crystalline form of sodium diformylamide.
摘要:
Method for determining a particular characteristic value of an effect compartment, such as the exit rate constant, after administration of a drug to a central compartment coupled to the effect compartment. Drug concentrations in the effect compartment are ascertained as a function of the exit rate constant, and a measured effect of the drug is obtained. A hysteresis loop between the drug concentrations in the effect compartment and the measured effect is graphically formed, and the hysteresis loop is collapsed by varying the exit rate constant of the effect compartment. A pharmacodynamic model which fits the curve of the collapsed hysteresis loop is selected, and a predicted effect is obtained in accordance with the selected pharmacodynamic model and the drug concentrations in the effect compartment. An error between the predicted effect and the measured effect is calculated, and the exit rate constant of the effect compartment is then adjusted until the calculated error between the predicted effect and the measured effect is minimized, thus obtaining the exit rate constant of the effect compartment. A dosing regimen for the drug is then designed in accordance with the exit rate constant at which the calculated error is minimized.
摘要:
An amino-acid ester compound can be cyclized into a cyclic amido-carbonyl compound by contacting the amino-acid ester compound in a liquid medium with a heterogeneous acidic ion-exchange substance. For example, 2-hydroxy-3-(2-aminophenylthio)-3-(4-methoxyphenyl)propionic acid, methyl ester, threo form, can be cyclized in an aqueous mixture into cis-2-(4-methoxyphenyl)-3-hydroxy-2,3-dihydro-1,5-benzothiazepin-4(5H)-one by employing a sulfonated polystyrene-divinylbenzene ion-exchange resin in its acid form, e.g., Dowex 50X4-400, at yields exceeding 85 percent of theory, and the product can be used to make diltiazem hydrochloride.
摘要:
The present invention provides various processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinemethanol. These processes may be characterized by scheme (A).
摘要:
A mouse anti-human MP52 monoclonal antibody which binds to dimeric human MP52 but not to monomeric human MP52. This mouse monoclonal antibody comprising IgG and having a high specificity can be obtained by sensitizing mice with human MP52 (CHO-MP52) produced in CHO cells and human MP52 (rhMP52) produced in escherichia coli. This antibody is useful in, for example, purifying or assaying human MP52 produced by genetic engineering techniques.
摘要:
The purpose is to provide a monomer protein effective for prevention and therapeutic treatment of bone and/or cartilage diseases. Said purpose is achieved by a monomer protein having an amino acid sequence of which cysteine contributing to dimer formation of a protein belonging to TGF-β superfamily has been replaced with another amino acid. In comparison with the corresponding dimer protein, the monomer protein has a two-fold higher activity in an osteoblast cell line to induce differentiation. Other amino acids are exemplified by serine, threonine, alanine, and valine, and preferably alanine. Said protein is prepared by using Escherichia coli, yeast, insect cells, and mammal cells that have been transformed by a plasmid having a DNA sequence capable of expression of said monomer protein.
摘要:
The invention concerns novel crystalline forms of 1S-[1alpha(2S*, 3R*),9alpha]-6, 10-dioxo-N- (2-ethoxy-5 -oxo-tetrahydro-3 -furanyl)-9-[[( 1-isoquinolyl) carbonyl]-amino] octahydro-6H -piridazino[1, 2-a][1,2]diazepin-1 -carboxamide, anhydrous (form A) and hydrated (form B), the method for preparing them, their use as medicine and the pharmaceutical compositions containing them.